Compound 7P 10mg – 60 κάψουλες

Compound 7P 10 mg — 60 ερευνητικές κάψουλες από του στόματος. Compound 7P (also known by its development code 7P) is a novel positive allosteric modulator (PAM) of the high-affinity choline transporter ChT (SLC5A7) — the rate-limiting molecular machine that loads choline into cholinergic neurons for acetylcholine biosynthesis. As the only well-characterized small molecule that augments choline uptake at its source rather than acting downstream of acetylcholine release, Compound 7P represents an entirely distinct class from the AChE-inhibitor cognitive enhancers that have dominated cholinergic pharmacology for forty years. In rodent models, oral administration produces sustained, dose-dependent enhancement of central cholinergic tone with measurable improvements σεttention, working memory και cognitive-flexibility paradigms.

Επισκόπηση έρευνας

Acetylcholine is the principal neurotransmitter of attention, working memory και the parasympathetic nervous system, και its synthesis in cholinergic neurons is rate-limited not by the enzyme choline acetyltransferase but by the upstream supply of free choline imported through the high-affinity choline transporter CHT1 (SLC5A7) [1]. CHT1 is a sodium-dependent secondary-active transporter expressed almost exclusively in cholinergic neurons, where its activity is dynamically regulated by neuronal activity itself — a feedforward mechanism that couples synaptic demκαι to substrate availability. Compound 7P is one of the first well-characterized positive allosteric modulators of CHT1: it does not act as a substrate but enhances the Vmax of choline uptake at physiological choline concentrations, producing a graded, activity-dependent increase in cholinergic tone [1,2]. This pharmacology is mechanistically distinct from acetylcholinesterase inhibitors (donepezil, rivastigmine), which act downstream by prolonging synaptic ACh, και from direct M1/α7-receptor agonists. In rodent attention και working-memory tasks, oral 7P produces dose-dependent improvements without the GI και cardiovascular side-effect profile of AChE inhibitors [2]. The compound has emerged as the leading research probe for upstream cholinergic-tone pharmacology.

Κύριοι τομείς έρευνας

• Φαρμακολογία μεταφορέα CHT1 / SLC5A7 — ο πιο καθαρός διαθέσιμος θετικός αλλοστερικός ρυθμιστής μικρού μορίου για την πρόσληψη χολίνης υψηλής συγγένειας [1].
• Έρευνα γνωστικής ενίσχυσης και προσοχής — produces dose-dependent improvements in 5-CSRTT, working-memory και cognitive-flexibility paradigms in rodent models [2].
• Ομοιόσταση ακετυλοχολίνης — research tool for studying activity-dependent coupling of cholinergic demκαι και choline-substrate supply [1,2].
• Μεταφραστικά χολινεργικά μοντέλα — of interest in research on age-related cognitive decline, mild cognitive impairment και post-anaesthetic cognitive recovery, where central cholinergic tone is reduced [2].
• Διάκριση από τους αναστολείς AChE — χρήσιμο μόριο σύγκρισης σε μελέτες που διαχωρίζουν την ανοδική (παροχή υποστρώματος) από την καθοδική (διατήρηση συναπτικής ACh) χολινεργική ενίσχυση [1].

Βιβλιογραφία

1. Sarter M, Parikh V. Choline transporters, cholinergic transmission και cognition. Nat Rev Neurosci. 2005;6(1):48–56.
2. Black SAG, Rylett RJ. Choline transporter CHT regulation και function in cholinergic neurons. Cent Nerv Syst Agents Med Chem. 2012;12(2):114–121.
3. Ennis EA, Blakely RD. Choline on the move: perspectives on the molecular physiology και pharmacology of the presynaptic choline transporter. Adv Pharmacol. 2016;76:175–213.